Cover Image
市場調查報告書

巨細胞病毒(HHV-5)感染疾病:開發中產品分析

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229755
出版日期 內容資訊 英文 177 Pages
訂單完成後即時交付
價格
Back to Top
巨細胞病毒(HHV-5)感染疾病:開發中產品分析 Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 177 Pages
簡介

巨細胞病毒(CMV)是皰疹病毒科的一種,是由病毒所引起的傳染性疾病。CMV會藉由唾液、尿來傳染。常見的症狀有發燒、肺炎、體重減輕、聽障、神經病變、發育障礙等。容易罹患的危險因子除了直接接觸受感染的表面及生物之外,還有免疫力不足、先天性因素等。可以血液檢查及尿液檢查診斷出。可以服藥(抗病毒藥等)來降低症狀、或改善生活習慣等。

本報告提供巨細胞病毒(HHV-5)感染疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

巨細胞病毒(HHV-5)感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Adicet Bio, Inc.
  • AIMM Therapeutics B.V.
  • Altor BioScience Corporation
  • Astellas Pharma Inc.
  • Atara Biotherapeutics, Inc.
  • Bionor Pharma ASA
  • Biotest AG
  • Cell Medica Limited
  • Chimerix, Inc.
  • China Biologic Products, Inc.
  • CyTuVax B.V.
  • Fate Therapeutics, Inc.
  • GlaxoSmithKline Plc
  • Hookipa Biotech AG.
  • Humabs BioMed SA.
  • Kadmon Corporation, LLC
  • Laboratoires Thea S.A.
  • Merck & Co., Inc.
  • Microbiotix, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Phoenix Biotechnology, Inc.
  • Savoy Pharmaceuticals, Inc.
  • Sigma-Tau S.p.A.
  • Trellis Bioscience, Inc.
  • Vakzine Projekt Management GmbH
  • VBI Vaccines Inc.
  • Vical Incorporated

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8694IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.

Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 7, 2, 17, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 7, 5 and 4 molecules, respectively.Cytomegalovirus (HHV-5) Infections.

Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cytomegalovirus (HHV-5) Infections Overview
  • Therapeutics Development
    • Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview
    • Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis
  • Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies
  • Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes
  • Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Cytomegalovirus (HHV-5) Infections - Products under Development by Companies
  • Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes
  • Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development
    • Adicet Bio, Inc.
    • AIMM Therapeutics BV
    • Astellas Pharma Inc
    • Atara Biotherapeutics Inc
    • AvidBiotics Corp
    • Biotest AG
    • Chimerix Inc
    • China Biologic Products Inc
    • CyTuVax BV
    • Fate Therapeutics Inc
    • GlaxoSmithKline Plc
    • Hookipa Biotech AG
    • Kadmon Corp LLC
    • Laboratoires Thea SA
    • Merck & Co Inc
    • Microbiotix Inc
    • Mymetics Corp
    • Novartis AG
    • Pfizer Inc
    • Phoenix Biotechnology Inc
    • Savoy Pharmaceuticals, Inc.
    • Sigma-Tau SpA
    • Themis Bioscience GmbH
    • Trellis Bioscience Inc
    • Vakzine Projekt Management GmbH
    • VBI Vaccines Inc
    • Vical Inc
  • Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AIC-387 - Drug Profile
    • AIC-476 - Drug Profile
    • AIC-813 - Drug Profile
    • AL-18 - Drug Profile
    • Antibody for Human Cytomegalovirus Infection - Drug Profile
    • ASP-0113 - Drug Profile
    • brincidofovir - Drug Profile
    • BT-084 - Drug Profile
    • Cellular Immunotherapy for Cytomegalovirus and Adenovirus Infections - Drug Profile
    • Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile
    • Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile
    • Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile
    • Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile
    • Cellular Immunotherapy for Cytomegalovirus Infections and GBM - Drug Profile
    • Cellular Immunotherapy for Infectious Disease - Drug Profile
    • Cellular Immunotherapy for Infectious Diseases - Drug Profile
    • Cellular Immunotherapy for Viral Infections - Drug Profile
    • Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile
    • Cellular Immunotherapy to Target CMV Antigen for Cytomegalovirus Infections - Drug Profile
    • Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
    • Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
    • Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
    • CMX-669 - Drug Profile
    • CSJ-148 - Drug Profile
    • CyMVectin - Drug Profile
    • cytomegalovirus (virus like particle) vaccine - Drug Profile
    • Cytomegalovirus (virus like particle) vaccine - Drug Profile
    • Cytomegalovirus vaccine - Drug Profile
    • Cytomegalovirus vaccine - Drug Profile
    • Cytomegalovirus vaccine - Drug Profile
    • filociclovir - Drug Profile
    • ganciclovir - Drug Profile
    • Gene Therapy for Cytomegalovirus Infections - Drug Profile
    • HB-101 - Drug Profile
    • letermovir - Drug Profile
    • maribavir - Drug Profile
    • MBX-2168 - Drug Profile
    • Monoclonal Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile
    • Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile
    • Monoclonal Antibody to Agonize LTbR for CMV Infection - Drug Profile
    • Pentamer - Drug Profile
    • Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile
    • PepVax - Drug Profile
    • ProTmune - Drug Profile
    • PTX-3 - Drug Profile
    • RBT-301 - Drug Profile
    • Recombinant Peptide for Infectious Diseases - Drug Profile
    • Recombinant Protein for CMV - Drug Profile
    • RKP-00156 - Drug Profile
    • Small Molecule for Cytomegalovirus - Drug Profile
    • Small Molecules for CMV Infections - Drug Profile
    • Small Molecules for CMV infections and Cancer - Drug Profile
    • Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile
    • Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile
    • Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile
    • Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections - Drug Profile
    • Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile
    • Triplex - Drug Profile
    • TRL-345 - Drug Profile
    • V-160 - Drug Profile
    • VBI-1501A - Drug Profile
    • Viralym-C - Drug Profile
    • Viroprev - Drug Profile
    • VPM-2001 - Drug Profile
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects
  • Cytomegalovirus (HHV-5) Infections - Discontinued Products
  • Cytomegalovirus (HHV-5) Infections - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2016
  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Adicet Bio, Inc., H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics BV, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by AvidBiotics Corp, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix Inc, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Inc, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by CyTuVax BV, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corp LLC, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Laboratoires Thea SA, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Mymetics Corp, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Pfizer Inc, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Sigma-Tau SpA, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, H2 2016
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..1), H2 2016
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..2), H2 2016
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..3), H2 2016
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..4), H2 2016
  • Cytomegalovirus (HHV-5) Infections - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2016
  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top